Gastroenterology

TNFalpha blocker are biologic agents, which are used for the treatment of inflammatory diseases such as Ulcerative Colitis, Crohns disease and Rheumatoid Arthritis. Infliximab as well as [...]

Molander et al. investigated if concentrations of fecal calprotectin can be used for predicting relaps after stopping TNFα blocking therapy in patients with Ulcerative Colitis and Morbus Crohn.

Study about first randomized, controlled testing shows that clinical treatment decisions based on therapeutic drug monitoring (TDM) is superior to dose-intensification strategy.

Ann Gils and her colleagues from KU Leuven evaluated if the biosimilars were equally well quantified as the original infliximab (IFX) drug in their clinically validated infliximab assay.

RIDASCREEN® IFX Monitoring is an enzyme linked immunoassay intended for the quantitative determination of infliximab (IFX, anti-TNFα) in human serum and plasma. 

About 50 % of Type-1-Diabetics, 33 % Type-2-Diabetics and 75 – 80 % Mucoviscidosis patients develop exocrine pancreatic insufficiency in the course of their illness (Hardt PD, [...]